Final results from the pivotal PRESERVE trial (NCT04972097) have been published in European Urology, suggesting that irreversible electroporation (IRE) with the NanoKnife System is a safe and ...

Treatment with mitomycin for intravesical solution (Zusduri, formerly UGN-102) was associated with durable, long-term complete responses (CRs) in patients with low-grade, intermediate-risk non–muscle ...

One consideration is the setting in which the procedure is performed. The FDA recently expanded the label for the Rezūm System, which now includes prostate volumes up to 150 cm 3, In this interview, ...

Panelists discuss the critical unmet need for more personalized treatment in non–muscle-invasive bladder cancer (NMIBC), emphasizing the role of biomarkers, emerging modalities like radiation, and ...

In this video, Bridget Lang Findlay, MD, a reconstructive urologist with Mayo Clinic in Phoenix, Arizona, focuses on her study examining long-term bladder management strategies among women with spinal ...

The FDA and the French National Agency for the Safety of Medicines and Health Products (ANSM) have granted an investigational device exemption (IDE) clearance to a pivotal trial of the UroActive smart ...

Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.

Former President Joseph R. Biden’s recent diagnosis of metastatic prostate cancer has put prostate health back into the national spotlight. His courage in sharing his diagnosis, particularly at age 82 ...

Urology Times is the leading resource for urologists & allied health professionals offering clinical analysis, policy perspectives, & practical advice.

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 4-5 in opposition of a favorable benefit-risk profile for UGN-102 (mitomycin) intravesical solution in adult patients with recurrent low-grade ...

The application is seeking an expanded indication of talazoparib plus enzalutamide for mCRPC.